Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ASND
일자시간출처헤드라인심볼기업
2024/06/0105:26Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
2024/05/3021:30GlobeNewswire Inc.Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024NASDAQ:ASNDAscendis Pharma AS
2024/05/3005:08Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:ASNDAscendis Pharma AS
2024/05/1705:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
2024/05/1503:37Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
2024/05/1503:31GlobeNewswire Inc.Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
2024/05/1321:30GlobeNewswire Inc.Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialNASDAQ:ASNDAscendis Pharma AS
2024/05/0921:30GlobeNewswire Inc.Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024NASDAQ:ASNDAscendis Pharma AS
2024/05/0305:01GlobeNewswire Inc.Ascendis Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
2024/04/2605:46GlobeNewswire Inc.Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024NASDAQ:ASNDAscendis Pharma AS
2024/04/2421:30GlobeNewswire Inc.United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
2024/03/0801:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0611:39Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0522:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0522:04Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0521:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0505:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0505:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0504:54Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0504:36Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0504:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0422:30GlobeNewswire Inc.Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ASNDAscendis Pharma AS
2024/03/0201:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/03/0107:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/02/2906:49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/02/2807:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/02/2205:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/02/1707:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/02/1707:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
2024/02/1707:14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
 검색 관련기사 보기:NASDAQ:ASND